Takeda and partner Amylin say they are discontinuing development of an investigational combination obesity therapy consisting of the latter’s diabetes drug Symlin and metreleptin.
The companies say the joint decision is based on a “commercial reassessment” of the drug, which comprises Symlin (pramlintide), an analogue of amylin, and metreleptin, an analogue of leptin. which had been in Phase II studies as a twice-a-day injection formulation. Takeda says the review took into account “a revised development plan as well as evolving dynamics within the obesity therapeutic area”.
The companies said they will continue to evaluate other assets as potential candidates for obesity and related indications under the terms of their existing collaboration.
Christian Weyer, head of R&D at Amylin, said “the interplay of hormonal signals, such as amylin and leptin, plays a crucial role in the regulation of body weight” and “advances in peptide engineering and delivery may help us leverage this biology to develop a therapy with less frequent dosing”.
